glp 1 agonist dementia Repurposing glucagon-like peptide-1 receptor agonists for the treatment of neurodegenerative disorders Can GLP-1 agonists and SGLT-2

It is not known if CONTRAVE changes your risk of heart problems or stroke or of death due to heart problems or stroke

GLP-1 RAs mimic the effects of native GLP-1, which increases insulin secretion, inhibits glucagon secretion, increases satiety, and slows gastric emptying

RDs also can advocate for the safe and proper use of weight management medications in tandem with promoting the critical roles of healthful eating, lifestyle modifications, and medication adherence

In March 2024 the FDA approved semaglutide to help to lower the risk of cardiovascular death, heart attack and stroke in overweight or obese patients (Patchen)

Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al